L-asparaginase and PEG asparaginase- past, present, and future

Leukemia and Lymphoma

Volumn 10, Issue S1, 1993, Pages 153-157

  Keating, Michael J ^a   Holmes, Romayne ^a   Lerner, Susan ^a   Ho, Dah Hsi ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Asparaginase; PEG; Polyethylene glycol

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; ASPARAGINE; ASPARTATE AMMONIA LIGASE; CYTARABINE; MACROGOL; METHOTREXATE; NEUTRALIZING ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; AMINO ACID BLOOD LEVEL; ANAPHYLACTIC SHOCK; BONE MARROW SUPPRESSION; BRONCHOSPASM; CELL VIABILITY; CHILD; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERANCE; DRUG UPTAKE; EDEMA; ENZYME ACTIVE SITE; HODGKIN DISEASE; HUMAN; HYPOALBUMINEMIA; LEUKEMIA CELL; LIVER DYSFUNCTION; LYMPHOMA; MYELOMA; NAUSEA; REMISSION; RETICULOENDOTHELIAL SYSTEM; VOMITING;

ADOLESCENT; ADULT; AGED; ANIMAL; ASPARAGINASE; HUMAN; LEUKEMIA; LYMPHOMA; MIDDLE AGE; POLYETHYLENE GLYCOLS;

EID: 0027536607     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199309149129     Document Type: Article

References (49)

1. Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum
2. Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects
3. L-asparaginase therapy for leukemia
4. Response to highly purified L-asparaginase during therapy of acute leukemia
5. L-asparaginase: clinical, biochemical, pharmacological and immunological studies
6. Anaphylactoid reactions to Esch-erichia coli and Erwinia asparaginase in children with leukemia and lymphoma
7. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct
8. L-asparaginase resistance in human leukemia-asparaginase synthetase
9. Therapy of neo-plasia with asparaginase
10. Distinctive sensitivity of some T-leukemia cell lines to L-asparaginase
11. Amino acid levels following L-asparaginase amidohydrolase (EC.3.5.1.1.) therapy
12. Asparagine synthetase in normal and malignant tissues; correlation with tumor sensitivity to asparaginase
13. Clinical pharmacology of polyethylene glycol-L-as-paraginase
14. Human pharmacology and toxicology of succinylated Acinetobacter glutaminase-asparaginase
15. Toxic and antineoplastic effects of L-asparaginase
16. Inhibition of leukemias in man by L-asparaginase
17. L-asparaginase and human malignant disease
18. Clinical results of treatment with E. coli L-asparaginase in adults with leukemia, lymphoma, and solid tumors
19. Acute lympho-blastic leukemia in childhood
20. The Berlin childhood acute lympho-blastic leukemia therapy study, 1970–1976
21. Improved disease-free survival of children with acute lympho-blastic leukemia at high risk for early relapse with the New York regimen-a new intensive therapy protocols: A report from the Childrens Study Group
22. L-asparaginase
23. The use of different forms of asparaginase with particular reference to Erwinia carotovorum
24. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli
25. Schedule-dependent synergism and antagonism between methotrexate and asparaginase
26. Schedule-dependent synergy and antagonism between high-dose l-β-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia
27. Combination chemotherapy-Theory and practice
28. Refractory acute leukemia in adults treated with sequential collaspase and high-dose methotrexate
29. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia-a Cancer and Leukemia Group B study
30. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease
31. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia
32. L-asparaginase: Decreased toxicity with Erwinia Asparaginase used in MRC UKALL VLLL
33. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement-mediated mechanism
34. Biochemical and pharmacological studies with asparaginase in man
35. The use of polyethylene glycol-conjugated L-asparaginase in pediatric patients with prior hypersensitivity to native L-asparaginase
36. Toxicity of L-asparaginase in children with advanced leukemia
37. Toxicity of E. coli L-asparaginase in man
38. Current concepts: L-asparaginase
39. L-asparaginase lowers protein C antigen
40. Clotting complications of L-asparaginase therapy in children with ALL
41. Factor VIII/von Willebrand factor abnormalities during L-asparaginase treatment in patients with acute lymphoblastic leukemia
42. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia
43. Management of asparaginase-induced hemor-rhagic pancreatitis complicated by pseudocyst
44. Early detection of chemotherapy-related pancreatic enlargement in children using abdominal sonography
45. Severe hepatotoxicity from escherichia coli-L-asparaginase
46. Neurotoxicity due to CNS therapy for leukemia
47. Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits
48. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia
49. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols